glp 1 market size GLP-1 Analogues to Hit USD 1,062.90 Billion by 2035 Glp-1 Analogues Market Size, Share

Jamie Velazquez, PharmD

Although not fully clarified, the mechanism of action of GLP-1 RAs on fatty liver disease may be multifactorial

Some of the evaluated GLP-1 RAs were associated with significant increased risk of vomiting, in the following order: liraglutide (RR 3.8722 [95% CI 3.1510, 4.7585

GLP-1s by year and indication GLP-1s by indication and year GLP-1 pipeline FAQs On March 19, 2026, the FDA approved a new, high-dose semaglutide (Wegovy HD) injection (7.2 mg) for once-weekly, subcutaneous (SC) administration for weight reduction and long-term maintenance

doi:10.1016/j.cgh.2017.11.024 Although it was avoided in these cases, the risk for pulmonary aspiration in sedated or anesthetized patients with unprotected airways is concerning

But even with this limited use, their impact will be significant